CD4 antibody | YKIX302.9

100% Secure


Rat anti Dog CD4:Alexa Fluor® 488

Rat anti Dog CD4:Alexa Fluor® 647

Rat anti Dog CD4:APC

Rat anti Dog CD4:FITC

Rat anti Dog CD4:Pacific Blue®

Rat anti Dog CD4

Rat anti Dog CD4:RPE

Rat anti Dog CD4:RPE-Cy7

Product Type
Monoclonal Antibody
Clone
YKIX302.9
Isotype
IgG2a
Product CodeApplicationsDatasheetMSDSPack SizeList PriceQuantity
MCA1038A488 F 100 Tests/1ml
MCA1038A647 F 100 Tests/1ml
MCA1038APC F 100 Tests
MCA1038F F 100 Tests
MCA1038PB F 100 Tests/1ml
MCA1038GA C F 0.1 mg
MCA1038PE F 100 Tests/1ml
MCA1038PECY7 F 100 Tests/1ml
Rat anti Dog CD4 antibody, clone YKIX302.9, is a monoclonal antibody specific for the canine CD4 cell surface antigen. Clone YKIX302.9 was clustered at the first Canine Leukocyte Antigen Workshop (CLAW) [Cobbold et al. 1992] along with clone CA13.1E4.

Rat anti Dog CD4 antibody, clone YKIX302.9 partially depletes circulating T lymphocytes when administered in vivo, but alone is not sufficient to prolong allograft survival in a canine transplant model (Watson et al. 1993).

Uniquely amongst mammals, canine CD4 is expressed by neutrophils as well as by lymphocytes subsets Moore et al. 1992.

Product Details

Target Species
Dog
Product Form
Purified IgG conjugated to Alexa Fluor® 488 - liquid
Product Form
Purified IgG conjugated to Alexa Fluor® 647 - liquid
Product Form
Purified IgG conjugated to Allophycocyanin (APC) - lyophilised
Product Form
Purified IgG conjugated to Fluorescein Isothiocyanate Isomer 1 (FITC) - liquid
Product Form
Purified IgG conjugated to Pacific Blue® - liquid
Product Form
Purified IgG - liquid
Product Form
Purified IgG conjugated to R. Phycoerythrin (RPE) - lyophilized
Product Form
Purified IgG conjugated to R. Phycoerythrin (RPE)-Cy7 - lyophilised
Reconstitution
Reconstitute with 1.0 ml distilled water
Reconstitution
Reconstitute with 1.0 ml distilled water
Reconstitution
Reconstitute with 1ml distilled water
Care should be taken during reconstitution as the protein may appear as a film at the bottom of the vial. Bio-Rad recommend that the vial is gently mixed after reconstitution.
Preparation
Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
Preparation
Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
Preparation
Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
Preparation
Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
Preparation
Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
Preparation
Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
Preparation
Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant.
Preparation
Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
Buffer Solution
Phosphate buffered saline
Buffer Solution
Phosphate buffered saline
Buffer Solution
Phosphate buffered saline
Buffer Solution
Phosphate buffered saline
Buffer Solution
Phosphate buffered saline
Buffer Solution
Phosphate buffered saline
Buffer Solution
Phosphate buffered saline
Buffer Solution
Phosphate buffered saline
Preservative Stabilisers
0.09%Sodium Azide
1%Bovine Serum Albumin
Preservative Stabilisers
0.09%Sodium Azide
1%Bovine Serum Albumin
Preservative Stabilisers
0.09%Sodium Azide
1%Bovine Serum Albumin
5%Sucrose
Preservative Stabilisers
0.09%Sodium Azide
1%Bovine Serum Albumin
Preservative Stabilisers
0.09%Sodium Azide
1%Bovine Serum Albumin
Preservative Stabilisers
0.09% Sodium Azide (NaN3)
Preservative Stabilisers
0.09%Sodium Azide
1%Bovine Serum Albumin
5%Sucrose
Preservative Stabilisers
0.09% Sodium Azide (NaN3)
1% Bovine Serum Albumin
5% Sucrose
Carrier Free
Yes
Immunogen
Canine concanavilin A activated T cell blasts.
Approx. Protein Concentrations
IgG concentration 0.05 mg/ml
Approx. Protein Concentrations
IgG concentration 0.05 mg/ml
Approx. Protein Concentrations
IgG concentration 0.1 mg/ml
Approx. Protein Concentrations
IgG concentration 0.1 mg/ml
Approx. Protein Concentrations
IgG concentration 0.05 mg/ml
Approx. Protein Concentrations
IgG concentration 1.0 mg/ml
Fusion Partners
Spleen cells from immunised DA rats were fused with cells of the Y3/Ag1.2.3 rat myeloma cell line.

Storage Information

Storage
Store at +4oC or at -20oC if preferred.

This product should be stored undiluted.

Storage in frost free freezers is not recommended. This product is photosensitive and should be protected from light.

Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
Storage
Store at +4oC or at -20oC if preferred.

This product should be stored undiluted.

Storage in frost free freezers is not recommended. This product is photosensitive and should be protected from light.

Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
Storage
Prior to reconstitution store at +4oC. Following reconstitution store at +4oC.

DO NOT FREEZE.

This product should be stored undiluted. This product is photosensitive and should be protected from light. Should this product contain a precipitate we recommend microcentrifugation before use.
Storage
Store at +4oC or at -20oC if preferred.

This product should be stored undiluted.

Storage in frost free freezers is not recommended. This product is photosensitive and should be protected from light.

Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
Storage
Store at +4oC or at -20oC if preferred.

This product should be stored undiluted.

Storage in frost free freezers is not recommended. This product is photosensitive and should be protected from light.

Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
Storage
Store at +4oC or at -20oC if preferred.

This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
Storage
Prior to reconstitution store at +4oC. Following reconstitution store at +4oC.

DO NOT FREEZE.

This product should be stored undiluted. This product is photosensitive and should be protected from light. Should this product contain a precipitate we recommend microcentrifugation before use.
Storage
Prior to reconstitution store at +4oC.
After reconstitution store at +4oC.
DO NOT FREEZE. This product should be stored undiluted. This product is photosensitive and should be protected from light.
Shelf Life
18 months from date of despatch.
Shelf Life
18 months from date of despatch.
Shelf Life
18 months from date of reconstitution.
Shelf Life
18 months from date of despatch.
Shelf Life
18 months from date of despatch.
Shelf Life
18 months from date of despatch.
Shelf Life
12 months from date of reconstitution.
Shelf Life
12 months from date of reconstitution

More Information

UniProt
P33705 Related reagents
Entrez Gene
CD4 Related reagents
GO Terms
GO:0007155 cell adhesion
GO:0016021 integral to membrane
GO:0006955 immune response
GO:0045058 T cell selection
Acknowledgements
This product is provided under an intellectual property licence from Life Technologies Corporation. The transfer of this product is contingent on the buyer using the purchase product solely in research, excluding contract research or any fee for service research, and the buyer must not sell or otherwise transfer this product or its components for (a) diagnostic, therapeutic or prophylactic purposes; (b) testing, analysis or screening services, or information in return for compensation on a per-test basis; (c) manufacturing or quality assurance or quality control, or (d) resale, whether or not resold for use in research. For information on purchasing a license to this product for purposes other than as described above, contact Life Technologies Corporation, 5791 Van Allen Way, Carlsbad CA 92008 USA or outlicensing@thermofisher.com
Acknowledgements
This product is provided under an intellectual property licence from Life Technologies Corporation. The transfer of this product is contingent on the buyer using the purchase product solely in research, excluding contract research or any fee for service research, and the buyer must not sell or otherwise transfer this product or its components for (a) diagnostic, therapeutic or prophylactic purposes; (b) testing, analysis or screening services, or information in return for compensation on a per-test basis; (c) manufacturing or quality assurance or quality control, or (d) resale, whether or not resold for use in research. For information on purchasing a license to this product for purposes other than as described above, contact Life Technologies Corporation, 5791 Van Allen Way, Carlsbad CA 92008 USA or outlicensing@thermofisher.com
Acknowledgements
This product is provided under an intellectual property licence from Life Technologies Corporation. The transfer of this product is contingent on the buyer using the purchased product solely in research, excluding contract research or any fee for service research, and the buyer must not sell or otherwise transfer this product or its components for (a) diagnostic, therapeutic or prophylactic purposes; (b) testing, analysis or screening services, or information in return for compensation on a per-test basis; (c) manufacturing or quality assurance or quality control, or (d) resale, whether or not resold for use in research. For information on purchasing a license to this product for purposes other than as described above, contact Life Technologies Corporation, 5791 Van Allen Way, Carlsbad CA 92008 USA or outlicensing@thermofisher.com
Acknowledgements
Cy® and CyDye® are registered trademarks of GE Healthcare
Regulatory
For research purposes only

Applications of CD4 antibody

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit the antibody protocols page.
Application Name Verified Min Dilution Max Dilution
Flow Cytometry Neat 1/10
Flow Cytometry Neat 1/10
Flow Cytometry Neat 1/10
Flow Cytometry Neat
Flow Cytometry Neat 1/5
Flow Cytometry 1/50 1/100
Immunohistology - Frozen
Flow Cytometry Neat 1/10
Flow Cytometry Neat
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
Flow Cytometry
Use 10ul of the suggested working dilution to label 106 cells or 100ul whole blood.
Flow Cytometry
Use 10ul of the suggested working dilution to label 106 cells or 100ul whole blood.
Flow Cytometry
Use 10ul of the suggested working dilution to label 106 cells or 100ul whole blood.
Flow Cytometry
Use 10ul of the suggested working dilution to label 106 cells or 100ul whole blood.
Flow Cytometry
Use 10ul of the suggested working dilution to label 106 cells or 100ul whole blood.
Flow Cytometry
Use 10ul of the suggested working dilution to label 106 cells or 100ul whole blood.
Flow Cytometry
Use 10ul of the suggested working dilution to label 106 cells or 100ul whole blood.
Flow Cytometry
Use 10ul of the suggested working dilution to label 1x106 cells in 100ul

Secondary Antibodies Available

Description Product Code Pack Size Applications List Price Quantity
Goat anti Rat IgG:Alk. Phos. (Mouse Adsorbed) STAR131A 1 ml C E P WB
Goat anti Rat IgG:Biotin (Mouse Adsorbed) STAR131B 0.5 mg C E IF P WB
Rabbit F(ab')2 anti Rat IgG:Dylight®800 STAR16D800GA 0.1 mg F IF WB
Rabbit F(ab')2 anti Rat IgG:FITC STAR17B 1 mg F
Rabbit F(ab')2 anti Rat IgG:HRP STAR21B 1 mg C E P RE
Goat F(ab')2 anti Rat IgG:FITC (Mouse Adsorbed) STAR69 0.5 ml F
Goat anti Rat IgG:DyLight®649 (Mouse Adsorbed) STAR71D649GA 0.1 mg F IF
Goat anti Rat IgG:Dylight®800 (Mouse Adsorbed) STAR71D800GA 0.1 mg F IF WB
Goat anti Rat IgG:HRP (Mouse Adsorbed) STAR72 0.5 mg C E P
Goat F(ab')2 anti Rat IgG:RPE (Mouse Adsorbed) STAR73 0.5 ml F

Negative Isotype Controls Available

Description Product Code Pack Size Applications List Price Quantity
Rat IgG2a Negative Control:Alexa Fluor® 488 MCA1212A488 100 Tests/1ml F
Rat IgG2a Negative Control:Alexa Fluor® 647 MCA1212A647 100 Tests/1ml F
Rat IgG2a Negative Control:Alexa Fluor® 647 MCA6005A647 100 Tests/1ml F
Rat IgG2a Negative Control:APC MCA6005APC 100 Tests F
Rat IgG2a Negative Control:FITC MCA1212F 100 Tests F
Rat IgG2a Negative Control:FITC MCA6005F 0.1 mg F
Rat IgG2a Negative Control:Pacific Blue® MCA1212PB 100 Tests/1ml F
Rat IgG2a Negative Control:PacificBlue® MCA6005PB 100 Tests/1ml F
Rat IgG2a Negative Control:RPE MCA1212PE 100 Tests F
Rat IgG2a Negative Control:RPE MCA6005PE 100 Tests F
Rat IgG2a Negative Control:RPE-Cy7 MCA6005PECY7 100 Tests/1ml F

Application Based External Images

Flow Cytometry

Product Specific References

Source Reference

  1. Cobbold, S. & Metcalfe, S. (1994) Monoclonal antibodies that define canine homologues of human CD antigens: summary of the First International Canine Leukocyte Antigen Workshop (CLAW).
    Tissue Antigens. 43 (3): 137-54.

References for CD4 antibody

  1. Schaut, R.G. et al. (2016) Recovery of antigen-specific T cell responses from dogs infected with Leishmania (L.) infantum by use of vaccine associated TLR-agonist adjuvant.
    Vaccine. 34 (44): 5225-34.
  2. Gorman, S.D. et al. (1994) Isolation and expression of cDNA encoding the canine CD4 and CD8 alpha antigens.
    Tissue Antigens. 43 (3): 184-8.
  3. Watson, C.J. et al. (1993) CD4 and CD8 monoclonal antibody therapy: strategies to prolong renal allograft survival in the dog.
    Br J Surg. 80 (11): 1389-92.
  4. Papadogiannakis, E.I. et al. (2009) Determination of intracellular cytokines IFN-gamma and IL-4 in canine T lymphocytes by flow cytometry following whole-blood culture.
    Can J Vet Res. 73 (2): 137-43.
  5. Bauer. T.R. Jr. et al. (2006) Correction of the disease phenotype in canine leukocyte adhesion deficiency using ex vivo hematopoietic stem cell gene therapy.
    Blood. 108: 3313-20.
  6. Reis, A.B. et al. (2006) Phenotypic features of circulating leucocytes as immunological markers for clinical status and bone marrow parasite density in dogs naturally infected by Leishmania chagasi.
    Clin Exp Immunol. 146: 303-11.
  7. Araújo, M.S. et al. (2011) Immunological changes in canine peripheral blood leukocytes triggered by immunization with first or second generation vaccines against canine visceral leishmaniasis.
    Vet Immunol Immunopathol. 141: 64-75.
  8. Benyacoub, J. et al. (2003) Supplementation of food with Enterococcus faecium (SF68) stimulates immune functions in young dogs.
    J Nutr. 133: 1158-62.
  9. Bund, D. et al. (2010) Canine-DCs using different serum-free methods as an approach to provide an animal-model for immunotherapeutic strategies.
    Cell Immunol. 263: 88-98.
  10. Estrela-Lima, A. et al. (2010) Immunophenotypic features of tumor infiltrating lymphocytes from mammary carcinomas in female dogs associated with prognostic factors and survival rates.
    BMC Cancer. 10: 256.
  11. Out, T.A. et al. (2002) Local T-cell activation after segmental allergen challenge in the lungs of allergic dogs.
    Immunology. 105: 499-508.
  12. Boggiatto, P.M. et al. (2010) Immunologic indicators of clinical progression during canine Leishmania infantum infection.
    Clin Vaccine Immunol. 17: 267-73.
  13. Mitchell, L. et al. (2012) Clinical and immunomodulatory effects of toceranib combined with low-dose cyclophosphamide in dogs with cancer.
    J Vet Intern Med. 26: 355-62.
  14. Tominaga, M. et al. (2010) Flow cytometric analysis of peripheral blood and tumor-infiltrating regulatory T cells in dogs with oral malignant melanoma.
    J Vet Diagn Invest. 22: 438-41.
  15. Figueiredo, M.M. et al. (2014) Expression of Regulatory T Cells in Jejunum, Colon, and Cervical and Mesenteric Lymph Nodes of Dogs Naturally Infected with Leishmania infantum.
    Infect Immun. 82: 3704-12.
  16. Aresu, L. et al. (2014) VEGF and MMP-9: biomarkers for canine lymphoma.
    Vet Comp Oncol. 12: 29-36.
  17. Costa-Pereira, C. et al. (2015) One-year timeline kinetics of cytokine-mediated cellular immunity in dogs vaccinated against visceral leishmaniasis.
    BMC Vet Res. 11 (1): 92.
  18. Hauck, V. et al. (2016) Increased numbers of FoxP3-expressing CD4(+)  CD25(+) regulatory T cells in peripheral blood from dogs with atopic dermatitis and its correlation with disease severity.
    Vet Dermatol. 27 (1): 26-e9.
  19. Riondato, F. et al. (2015) Analytical and diagnostic validation of a flow cytometric strategy to quantify blood and marrow infiltration in dogs with large b-cell lymphoma.
    Cytometry B Clin Cytom. Dec 13. [Epub ahead of print]
  20. Miranda, S. et al. (2007) Characterization of circulating lymphocyte subpopulations in canine leishmaniasis throughout treatment with antimonials and allopurinol.
    Vet Parasitol. 144 (3-4): 251-60.
  21. Yamaya, Y. & Watari, T. (2015) Increased proportions of CCR4(+) cells among peripheral blood CD4(+) cells and serum levels of allergen-specific IgE antibody in canine chronic rhinitis and bronchitis.
    J Vet Med Sci. 77 (4): 421-5.
  22. Schaut, R.G. et al. (2016) Regulatory IgDhi B Cells Suppress T Cell Function via IL-10 and PD-L1 during Progressive Visceral Leishmaniasis.
    J Immunol. 196 (10): 4100-9.
  23. Tagawa, M. et al. (2016) Evaluation of Costimulatory Molecules in Peripheral Blood Lymphocytes of Canine Patients with Histiocytic Sarcoma.
    PLoS One. 11 (2): e0150030.
  24. Munhoz, T.D. et al. (2016) Regulatory T cells in dogs with multicentric lymphoma: peripheral blood quantification at diagnosis and after initial stage chemotherapy
    Arq. Bras. Med. Vet. Zootec. 68 (1): 1-9.
  25. Miller, J. et al. (2015) Humoral and Cellular Immune Response in Canine Hypothyroidism.
    J Comp Pathol. 153 (1): 28-37.
  26. Duz AL et al. (2014) The TcI and TcII Trypanosoma cruzi experimental infections induce distinct immune responses and cardiac fibrosis in dogs.
    Mem Inst Oswaldo Cruz. 109 (8): 1005-13.
  27. Gelain, M.E. et al. (2014) CD44 in canine leukemia: analysis of mRNA and protein expression in peripheral blood.
    Vet Immunol Immunopathol. 159 (1-2): 91-6.
  28. Viana, K.F. et al. (2015) Setting the proportion of CD4+ and CD8+ T-cells co-cultured with canine macrophages infected with Leishmania chagasi.
    Vet Parasitol. 211 (3-4): 124-32.
  29. Viana, K.F. et al. (2016) Application of rapid in vitro co-culture system of macrophages and T-cell subsets to assess the immunogenicity of dogs vaccinated with live attenuated Leishmania donovani centrin deleted parasites (LdCen-/-).
    Parasit Vectors. 9: 250.
  30. Michael HT et al. (2013) Isolation and characterization of canine natural killer cells.
    Vet Immunol Immunopathol. 155 (3): 211-7.
  31. Mitchell, L. et al. (2012) Induction of remission results in spontaneous enhancement of anti-tumor cytotoxic T-lymphocyte activity in dogs with B cell lymphoma.
    Vet Immunol Immunopathol. 145 (3-4): 597-603.
  32. Bonnefont-Rebeix, C. et al. (2016) Characterization of a novel canine T-cell line established from a spontaneously occurring aggressive T-cell lymphoma with large granular cell morphology.
    Immunobiology. 221 (1): 12-22.
  33. Deravi, N. et al. (2017) Specific immunotypes of canine T cell lymphoma are associated with different outcomes.
    Vet Immunol Immunopathol. 191: 5-13.
  34. Bahamondes, F. et al. (2017) Omental adipose tissue is a more suitable source of canine Mesenchymal stem cells.
    BMC Vet Res. 13 (1): 166.
  35. Pinheiro, D. (2011) Phenotypic and functional characterization of a CD4(+) CD25(high) FOXP3(high) regulatory T-cell population in the dog.
    Immunology. 132: 111-22.
  36. Withers, S.S. et al. (2018) Multi-color flow cytometry for evaluating age-related changes in memory lymphocyte subsets in dogs.
    Dev Comp Immunol. 87: 64-74.
  37. Declue, A.E. et al. (2018) Identification of immunologic and clinical characteristics that predict inflammatory response to C. Novyi-NT bacteriolytic immunotherapy.
    BMC Vet Res. 14 (1): 119.
  38. DaSilva, A.V.A. et al. (2018) Morphophysiological changes in the splenic extracellular matrix of Leishmania infantum-naturally infected dogs is associated with alterations in lymphoid niches and the CD4+ T cell frequency in spleens.
    PLoS Negl Trop Dis. 12 (4): e0006445.